1. Biomedical Technologies at Skolkovo Skolkovo Prof Igor Goryanin, Head of Biomedical Cluster, Skolkovo February 1, 2011 With help Skolkovo colleagues and McKinsey & Company
2. First steps, first achievements http://www.i-gorod.com/ From Presentation in Davos, January 25th, 2011
3. Town-planning concepts for Skolkovo Innovation Centre development (ОМА, AREP) OMA AREP Social Culture University Industry Commercial Residential Park & Ride
4. The MISSION of Skolkovo Skolkovo is to become an innovation hub that will stimulate innovative entrepreneurship and disseminate entrepreneurial culture across the country to integrate Russia into the global economy: Fostering advancement of human capital in Russia by attracting foreign specialists and creating conditions for local innovative talent development Creating globally competitive products and services based on cutting-edge research Establishing global innovative companies in Russia
5. Governance structure The government provides initial funding and signals credible commitment to support the project in the future The project is managed by a non-government foundation with an independent Board, regulated by a special law The Foundation is a doorkeeper, while all Skolkovo units (such as the Clusters) and residents are independent organizations Much of the real estate in Skolkovo will be built by private developers
11. Initial ideas Biomedicine: to focus in development , implementation and commercialization, long-term technology transfer in “P-4 Medicine” (Personalized, Participatory, Predictive and Preventive). Biopharmaceuticals: to establish Russian independence in the pharmaceutical sector from drug discovery to manufacturing (by 2015 many drug patents will expire, further weakening the financial foundation of the industry) Biomedical Informatics: to establish Russian independence in health informatics sector by establishing infrastructure, developing novel computational technologies, knowledge management, rational planning of biological and clinical experiments. Industrial Biotechnology and Bioenergetics: to develop alternative approaches in the bioenergy, and bioremediation sectors, to develop waste, and industrial by-products utilization technologies combined with energy production in multiple forms 10
12.
13. Relatively low infrastructure and equipment costs (e.g., versus drug production) and high interest from international partners to collaborate with local scientists also supports higher feasibility and opportunity
14. Can be an enabler of other areas as an early “proof of concept” for Skolkovo biotech cluster
18. Highly attractive driven by large existing domestic market of ~$1.5B, nearly 100% financed by Russian government healthcare budget spend and nearly all on imported drugs
19. Some areas (e.g. bio-similars) may have lower entry barriers and at the same time span across topics, ensuring broader impact
29. May become both feasible and highly attractive if government was to prioritise the area
30. Genetic modification of biomass, e.g. development of species relevant for a particular climate1 May be partially outside the current mandate SOURCE: Expert interviews; Team analysis
38. 14 Bio-Informatics Bio-Healthcare/ Bio-Pharma Biotech Prioritization Matrix Bio-Industrials Bio-Energy Attractiveness “Higher priority areas”: Expected to have highest proportion of high potential project proposals I III “Long term potential” Highly attractive but requires more capability and infrastructure building Vaccines and anti-infectives Oncology Companion diagnostics Blood Bulk/polymers Endocrine Regenerative medicine Drug development Cardiovascular Nuclear medicine National incubators CNS Food/feed Biosimilars Molecular medicine Musculo-skeletal Ethanol Gene therapy Bioremediation Agriculture “Lower priority areas” Select opportunities possible but expect less overall deal flow in these areas “No regret areas”: Relatively higher probability of success, can be leveraged to support other areas Preventive medicine Marine biotech Plant extracts Oleochemicals Biomass Biodiesel Sensory organs Genito-urinary Feasibility Strategic directions prioritization – Biomedical II IV SOURCE: Team analysis, Expert Interviews
80. Bioplastics (including biodegradable products) based on carbohydrates as starch, celluloseIII SOURCE: Expert interviews; Evaluate; IMS; Scientia Advisors; PWC; press search; team analysis
84. Area of high disruptive potential as evidenced by large R&D in the area, with high disruptive potential (e.g., USD 275 mn spent p.a. to catalogue gen. changes just in 20 types of cancer treat.)
89. Large current market (USD 27bn globally, USD 530mn in Russia), expected to grow rapidly (10% CAGR)
90. Clear support from the Russian government (e.g., declared interest and state purchases)
91. "Hot" area in global R&D, with strong "pockets" of capabilities in Russia (e.g., Gabibov’s lab)SOURCE: Expert interviews; Evaluate; IMS; Scientia Advisors; PWC; press search; team analysis
187. Common infrastructure (incl. management support) would create significant economies-of-scale for funding recipients
188. National incubatorsBio-Healthcare Priority areas: Talent development and diagnostics HIGH LEVEL ASSESSMENT Level 1 Direction Description/level 2 Rationale SOURCE: Expert interviews; press search; team analysis
192. Low barriers to entry: relatively low infrastructure/ start-up costs and high potential talent pool
193. Relatively low capital costs with big potential benefit, e.g., FDA estimates that 10% improvement in drug efficacy prediction rate can save USD 100mn devel. cost per drug
213. Work on preventing diseases, as opposed to curing them, using bio-informatics advances
214. Molecular diagnostics21 Not confined to molecular medicine but cross-cutting 2 Illustrative portion of preventative medicine SOURCE: Expert interviews; press search; team analysis
230. Russia has accumulated substantial research base of starch technology driven by significant local producing industry: main market players in Russia are Efremovsky, Gulkevichsky, Chaplygin, Zvyagin, Krahmaloproduct
231. Exists potential for development of niche products (e.g. for oil drilling)SOURCE: Expert interviews; team analysis
245. Currently negligible market size (no statistics) but with medium growth (construction of pipelines, new field exploration)
246. Lack of regulatory support (no pressure from the state to be environmentally more responsible)
247. Can be used immediately by existing industrySOURCE: Expert interviews; team analysis
248.
249. Application of molecular biological methods to marine and freshwater organisms, to produce foodstuffs, energy, drug compounds
250. Compounds derived from marine organisms used in healthcare (e.g red or green alga as anti-cancer compound)
251. Some disruptive potential but only 45 marine-derived natural products tested to be used as medical drugs in preclinical and clinical trials so far, only two have been developed into registered drugs
252. Fungi as a source for the compounds may be derived in extreme marine environments (cold water in Russia)
253. Research capability exists (Dalnevostochniy and Kaliningradskiy centres) but limited to only two institutes
254. Total spend on fish preservation and reproduction in Russia $50-70m
295. The expected impact 2015-2020 IP protected production of essential medicines, healthy food and animal feed, drug and food public safety Improved state health system through new technologies for diagnostics,prevention and treatment of diseases Increased renewables in the total energy balance. Improvement of ecological situation in Russian Federation by reduction ofemissions and conservation of biodiversity. New jobs created for urban and rural population with diverse Innovative economic development from scientific research originated from Skolkovo, Russia and by transfer of foreign technologies Establishment of the internationally recognized scientific and industrial biotech center The development of related industries (medicine and agriculture) through the creationof the additional demands from the biotechnology industry 33
296. 34 There is a unique opportunity for Russia Roger Kornberg, Nobel Laureate